Psilocybin as a Treatment for Anorexia Nervosa
About the study
Anorexia nervosa is a life-threatening condition for which there is no pharmacological treatment. There is growing evidence for the therapeutic use of psychedelic drugs such as psilocybin in mental health. This study aims to assess the feasibility and effectiveness of treating anorexia nervosa with psilocybin-assisted therapy. We would also like to gain more understanding of the brain mechanisms that may be involved to this treatment.
What will it involve?
Over a 6-week period, participants will receive three doses of psilocybin (up to 25 mg) in a therapeutic environment, each separated by two weeks. A final follow-up visit will be conducted two weeks after the final dosing session. There will be an extended remote follow-up period of 12-months.
Please note: The inclusion criteria below is not complete. For more information on the study, to view the full inclusion/exclusion criteria, and register to interest in this study please see the self-referral form here: https://imperial.eu.qualtrics.com/jfe/form/SV_2aXw4kjlXmWtC4J
This study is no longer accepting applications
Similar studies you may be eligible for...
-
Eating disorders
Brain, behaviour and genetics in eating disorder recovery (ESTRA)
Conducted by: King's College London
-
Eating disorders
ESTRA-bed
Conducted by: King's College London
-
Eating disorders
Evaluating a Model of Binge Eating
Conducted by: University of Edinburgh